Severe Symptoms, Ocular Pain Linked to Dry Eye Persistence

Share this content:
Severe Symptoms, Ocular Pain Linked to Dry Eye Persistence
Severe Symptoms, Ocular Pain Linked to Dry Eye Persistence

WEDNESDAY, Dec. 28, 2016 (HealthDay News) -- Severe dry eye symptoms and ocular pain at baseline are associated with persistent severe dry eye symptoms one year later, according to a study published online Dec. 22 in JAMA Ophthalmology.

Erin S. Ong, from the Miami Veteran Administration Medical Center, and colleagues conducted a longitudinal study among patients with a wide variety of dry eye symptoms and signs. The authors examined the change in dry eye symptom severity during one year and conducted baseline risk factor analysis for severe dry eye symptoms at one year.

The researchers found that 44.8 percent of the 120 patients with no symptoms or mild-to-moderate symptoms at baseline progressed to more severe symptoms at one year. Among the 62 patients with severe symptoms at baseline, 74.2 percent reported that severe symptoms persisted at one year. Severe dry eye symptoms, ocular pain, and neuropathic pain-like ocular symptoms were baseline ocular risk factors for severe dry eye symptoms at one year. Sleep disturbances, mental health status, non-ocular pain, and medications were non-ocular risk factors. The most significant risk factors in a multivariable analysis were sleep apnea (odds ratio [OR], 3.80; 95 percent confidence interval [CI], 1.00 to 14.49), Dry Eye Questionnaire 5 score (OR, 1.15; 95 percent CI, 1.02 to 1.30), and posttraumatic stress disorder score (OR, 1.04; 95 percent CI, 1.01 to 1.08).

"Our results suggest that pain perception and severity are important when evaluating and managing dry eye," the authors write.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Bavencio for Merkel Cell Carcinoma

FDA Approves Bavencio for Merkel Cell Carcinoma

Drug targets the PD-1/PD-L1 pathway; first sanctioned treatment in the United States

Heterogeneous Association for Alcohol, CVD Presentation

Heterogeneous Association for Alcohol, CVD Presentation

Non-drinking linked to increased risks of unstable angina, MI, heart failure, ischemic stroke, PAD, AAA

Mobile App Cuts In-Person Visits After Breast Reconstruction

Mobile App Cuts In-Person Visits After Breast Reconstruction

Number of visits down, increase in e-mails to doctors for ambulatory patients undergoing breast recon

is free, fast, and customized just for you!

Already a member?

Sign In Now »